TY - JOUR
T1 - Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice
AU - Wallace, Thomas L.
AU - Paetznick, Victor
AU - Cossum, Paul A.
AU - Lopez-Berestein, Gabriel
AU - Rex, John H.
AU - Anaissie, Elias
PY - 1997/10
Y1 - 1997/10
N2 - The purpose of this study was to examine the activity of liposomal nystatin against a disseminated Aspergillus fumigatus infection in neutropenic mice. Mice were made neutropenic with 5-fluorouracil and were administered the antifungal drug intravenously for 5 consecutive days beginning 24 h following infection. Liposomal nystatin, at doses as low as 2 mg/kg of body weight/day, protected neutropenic mice against Aspergillus-induced death in a statistically significant manner at the 50-day time point compared to either the no-treatment, the saline, or the empty-liposome group. This protection was approximately the same as that for free nystatin, a positive control. Histopathological results showed that liposomal nystatin cleared the lungs, spleen, pancreas, kidney, and liver of Aspergillus and that there was no organ damage at the day 5 time point, which was after only three doses of liposomal nystatin. Based on these results in mice, it is probable that liposomal nystatin will be effective against Aspergillus infection in humans.
AB - The purpose of this study was to examine the activity of liposomal nystatin against a disseminated Aspergillus fumigatus infection in neutropenic mice. Mice were made neutropenic with 5-fluorouracil and were administered the antifungal drug intravenously for 5 consecutive days beginning 24 h following infection. Liposomal nystatin, at doses as low as 2 mg/kg of body weight/day, protected neutropenic mice against Aspergillus-induced death in a statistically significant manner at the 50-day time point compared to either the no-treatment, the saline, or the empty-liposome group. This protection was approximately the same as that for free nystatin, a positive control. Histopathological results showed that liposomal nystatin cleared the lungs, spleen, pancreas, kidney, and liver of Aspergillus and that there was no organ damage at the day 5 time point, which was after only three doses of liposomal nystatin. Based on these results in mice, it is probable that liposomal nystatin will be effective against Aspergillus infection in humans.
UR - http://www.scopus.com/inward/record.url?scp=0030864107&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030864107&partnerID=8YFLogxK
U2 - 10.1128/aac.41.10.2238
DO - 10.1128/aac.41.10.2238
M3 - Article
C2 - 9333054
AN - SCOPUS:0030864107
SN - 0066-4804
VL - 41
SP - 2238
EP - 2243
JO - Antimicrobial agents and chemotherapy
JF - Antimicrobial agents and chemotherapy
IS - 10
ER -